Bismuth containing quadruple therapy and on the basis of the Ilaprazole of amoxicillin dual therapy for eradication of helicobacter pylori

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052308

Enrollment

Unknown

Registered

2021-10-24

Start date

2021-07-07

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The treatment of helicobacter pylori

Interventions

dual therapy in combination with GanHai stomach kang capsules:Taking Ilaprazole, amoxicillin, GanHai stomach kang capsules

dual therapy:Taking Ilaprazole, amoxicillin,

Bismuth containing quadruple therapy:Taking Ilaprazole, amoxicillin, furazolidone and bismuth agent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients (aged >=20 years) having H. pylori-positive chronic gastritis with/without peptic ulcers (duodenal or gastric ulcers)

Exclusion criteria

Exclusion criteria: Exclusion criteria included pregnancy or nursing, serious concomitant illness, malignant tumors, history of hypersensitivity to study drugs, severe ulcer bleeding, taking PPIs or antibiotics in the previous month. Patients without previous anti-H. pylori treatment were invited to receive the first-line regimens, whereas patients who had previously received anti-H. pylori therapies were invited to receive rescue regimens.

Design outcomes

Primary

Measure	Time frame
Delta Over Baseline;	—

Countries

China

Contacts

Public ContactBai Feihu

The Second Affiliated Hospital of Hai'nan Medical College

328473521@qq.com+86 18995181963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026